APO Research
Talk to an analyst

APO RESEARCH · REPORT

ADC Drug CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global ADC Drug CDMO Service Market Outlook and Growth Opportunities 2026

5 June 2026207 pages

Choose your research edition.

Industry ResearchADC Drug CDMO Service Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal ADC Drug CDMO Service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal ADC Drug CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal ADC Drug CDMO Service Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal ADC Drug CDMO Service Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global ADC Drug CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for ADC Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for ADC Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for ADC Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the ADC Drug CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the ADC Drug CDMO Service market include Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora and Aji Bio-Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global ADC Drug CDMO Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of ADC Drug CDMO Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents ADC Drug CDMO Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global ADC Drug CDMO Service market.

ADC Drug CDMO Service Segment by Company

Lonza Group

Merck KGaA

WuXi XDC

Abbvie

Piramal Pharma Solutions

Catalent

Sterling Pharma Solutions

Axplora

Aji Bio-Pharma

BSP Pharmaceuticals

Cerbios-Pharma

Goodwin Biotechnology

TOT Biopharm

Huadong Medicine

Innovent Biologics

Shanghai Henlius Biotech

ADC Drug CDMO Service Segment by Type

Cleavable Linkers

Non-cleavable Linkers

ADC Drug CDMO Service Segment by Application

Small and Medium-sized Pharmaceutical Companies

Large Pharmaceutical Companies

ADC Drug CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global ADC Drug CDMO Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the ADC Drug CDMO Service key companies, revenue, market share, and recent developments.

3. To split the ADC Drug CDMO Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions ADC Drug CDMO Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify ADC Drug CDMO Service significant trends, drivers, influence factors in global and regions.

6. To analyze ADC Drug CDMO Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ADC Drug CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of ADC Drug CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ADC Drug CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global ADC Drug CDMO Service industry.

Chapter 3: Detailed analysis of ADC Drug CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of ADC Drug CDMO Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of ADC Drug CDMO Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. ADC Drug CDMO Service Industry Trends Table 2. ADC Drug CDMO Service Industry Drivers Table 3. ADC Drug CDMO Service Industry Opportunities and Challenges Table 4. ADC Drug CDMO Service Industry Restraints Table 5. Global ADC Drug CDMO Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global ADC Drug CDMO Service Revenue Share by Company (2021-2026) Table 7. Global ADC Drug CDMO Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global ADC Drug CDMO Service Key Company Manufacturing Base & Headquarters Table 9. Global ADC Drug CDMO Service Company, Product Type & Application Table 10. Global ADC Drug CDMO Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global ADC Drug CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cleavable Linkers Table 15. Significant Companies of Non-cleavable Linkers Table 16. Global ADC Drug CDMO Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global ADC Drug CDMO Service Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global ADC Drug CDMO Service Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global ADC Drug CDMO Service Sales Value Share by Type (2021-2026) Table 20. Global ADC Drug CDMO Service Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Small and Medium-sized Pharmaceutical Companies Table 22. Significant Companies of Large Pharmaceutical Companies Table 23. Global ADC Drug CDMO Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global ADC Drug CDMO Service Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global ADC Drug CDMO Service Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global ADC Drug CDMO Service Sales Value Share by Application (2021-2026) Table 27. Global ADC Drug CDMO Service Sales Value Share by Application (2027-2032) Table 28. Global ADC Drug CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global ADC Drug CDMO Service Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global ADC Drug CDMO Service Sales Value Share by Region (2021-2026) Table 31. Global ADC Drug CDMO Service Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global ADC Drug CDMO Service Sales Value Share by Region (2027-2032) Table 33. Global ADC Drug CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global ADC Drug CDMO Service Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global ADC Drug CDMO Service Sales Value Market Share by Country (2021-2026) Table 36. Global ADC Drug CDMO Service Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global ADC Drug CDMO Service Sales Value Market Share by Country (2027-2032) Table 38. Lonza Group Company Information Table 39. Lonza Group Business Overview Table 40. Lonza Group ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Lonza Group ADC Drug CDMO Service Product Portfolio Table 42. Lonza Group Recent Development Table 43. Merck KGaA Company Information Table 44. Merck KGaA Business Overview Table 45. Merck KGaA ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Merck KGaA ADC Drug CDMO Service Product Portfolio Table 47. Merck KGaA Recent Development Table 48. WuXi XDC Company Information Table 49. WuXi XDC Business Overview Table 50. WuXi XDC ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. WuXi XDC ADC Drug CDMO Service Product Portfolio Table 52. WuXi XDC Recent Development Table 53. Abbvie Company Information Table 54. Abbvie Business Overview Table 55. Abbvie ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Abbvie ADC Drug CDMO Service Product Portfolio Table 57. Abbvie Recent Development Table 58. Piramal Pharma Solutions Company Information Table 59. Piramal Pharma Solutions Business Overview Table 60. Piramal Pharma Solutions ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Piramal Pharma Solutions ADC Drug CDMO Service Product Portfolio Table 62. Piramal Pharma Solutions Recent Development Table 63. Catalent Company Information Table 64. Catalent Business Overview Table 65. Catalent ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Catalent ADC Drug CDMO Service Product Portfolio Table 67. Catalent Recent Development Table 68. Sterling Pharma Solutions Company Information Table 69. Sterling Pharma Solutions Business Overview Table 70. Sterling Pharma Solutions ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Sterling Pharma Solutions ADC Drug CDMO Service Product Portfolio Table 72. Sterling Pharma Solutions Recent Development Table 73. Axplora Company Information Table 74. Axplora Business Overview Table 75. Axplora ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Axplora ADC Drug CDMO Service Product Portfolio Table 77. Axplora Recent Development Table 78. Aji Bio-Pharma Company Information Table 79. Aji Bio-Pharma Business Overview Table 80. Aji Bio-Pharma ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Aji Bio-Pharma ADC Drug CDMO Service Product Portfolio Table 82. Aji Bio-Pharma Recent Development Table 83. BSP Pharmaceuticals Company Information Table 84. BSP Pharmaceuticals Business Overview Table 85. BSP Pharmaceuticals ADC Drug CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. BSP Pharmaceuticals ADC Drug CDMO Service Product Portfolio Table 87. BSP Pharmaceuticals Recent Development Table 88. Cerbios-Pharma Company Information Table 89. Cerbios-Pharma Business Overview Table 90. Cerbios-Pharma ADC Drug CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Cerbios-Pharma ADC Drug CDMO Service Product Portfolio Table 92. Cerbios-Pharma Recent Development Table 93. Goodwin Biotechnology Company Information Table 94. Goodwin Biotechnology Business Overview Table 95. Goodwin Biotechnology ADC Drug CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Goodwin Biotechnology ADC Drug CDMO Service Product Portfolio Table 97. Goodwin Biotechnology Recent Development Table 98. TOT Biopharm Company Information Table 99. TOT Biopharm Business Overview Table 100. TOT Biopharm ADC Drug CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. TOT Biopharm ADC Drug CDMO Service Product Portfolio Table 102. TOT Biopharm Recent Development Table 103. Huadong Medicine Company Information Table 104. Huadong Medicine Business Overview Table 105. Huadong Medicine ADC Drug CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Huadong Medicine ADC Drug CDMO Service Product Portfolio Table 107. Huadong Medicine Recent Development Table 108. Innovent Biologics Company Information Table 109. Innovent Biologics Business Overview Table 110. Innovent Biologics ADC Drug CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Innovent Biologics ADC Drug CDMO Service Product Portfolio Table 112. Innovent Biologics Recent Development Table 113. Shanghai Henlius Biotech Company Information Table 114. Shanghai Henlius Biotech Business Overview Table 115. Shanghai Henlius Biotech ADC Drug CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Shanghai Henlius Biotech ADC Drug CDMO Service Product Portfolio Table 117. Shanghai Henlius Biotech Recent Development Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. ADC Drug CDMO Service Product Image Figure 2. Global ADC Drug CDMO Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global ADC Drug CDMO Service Market Size (2021-2032) & (US$ Million) Figure 4. Global ADC Drug CDMO Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cleavable Linkers Image Figure 8. Non-cleavable Linkers Image Figure 9. Global ADC Drug CDMO Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global ADC Drug CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global ADC Drug CDMO Service Sales Value Share by Type (2021-2032) Figure 12. Small and Medium-sized Pharmaceutical Companies Image Figure 13. Large Pharmaceutical Companies Image Figure 14. Global ADC Drug CDMO Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global ADC Drug CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global ADC Drug CDMO Service Sales Value Share by Application (2021-2032) Figure 17. Global ADC Drug CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global ADC Drug CDMO Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America ADC Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 20. North America ADC Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe ADC Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 22. Europe ADC Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific ADC Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific ADC Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America ADC Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 26. South America ADC Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa ADC Drug CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa ADC Drug CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt ADC Drug CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Cleavable Linkers
  • Non-cleavable Linkers
Applications
  • Small and Medium-sized Pharmaceutical Companies
  • Large Pharmaceutical Companies
Companies covered
  • Lonza Group
  • Merck KGaA
  • WuXi XDC
  • Abbvie
  • Piramal Pharma Solutions
  • Catalent
  • Sterling Pharma Solutions
  • Axplora
  • Aji Bio-Pharma
  • BSP Pharmaceuticals
  • Cerbios-Pharma
  • Goodwin Biotechnology
  • TOT Biopharm
  • Huadong Medicine
  • Innovent Biologics
  • Shanghai Henlius Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global ADC Drug CDMO Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global ADC Drug CDMO Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 ADC Drug CDMO Service Market Dynamics
  1. 2.1 ADC Drug CDMO Service Industry Trends
  2. 2.2 ADC Drug CDMO Service Industry Drivers
  3. 2.3 ADC Drug CDMO Service Industry Opportunities and Challenges
  4. 2.4 ADC Drug CDMO Service Industry Restraints
3 ADC Drug CDMO Service Market by Company
  1. 3.1 Global ADC Drug CDMO Service Company Revenue Ranking in 2025
  2. 3.2 Global ADC Drug CDMO Service Revenue by Company (2021-2026)
  3. 3.3 Global ADC Drug CDMO Service Company Ranking (2024-2026)
  4. 3.4 Global ADC Drug CDMO Service Company Manufacturing Base and Headquarters
  5. 3.5 Global ADC Drug CDMO Service Company Product Type and Application
  6. 3.6 Global ADC Drug CDMO Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global ADC Drug CDMO Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 ADC Drug CDMO Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 ADC Drug CDMO Service Market by Type
  1. 4.1 ADC Drug CDMO Service Type Introduction
  2. 4.1.1 Cleavable Linkers
  3. 4.1.2 Non-cleavable Linkers
  4. 4.2 Global ADC Drug CDMO Service Sales Value by Type
  5. 4.2.1 Global ADC Drug CDMO Service Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global ADC Drug CDMO Service Sales Value by Type (2021-2032)
  7. 4.2.3 Global ADC Drug CDMO Service Sales Value Share by Type (2021-2032)
5 ADC Drug CDMO Service Market by Application
  1. 5.1 ADC Drug CDMO Service Application Introduction
  2. 5.1.1 Small and Medium-sized Pharmaceutical Companies
  3. 5.1.2 Large Pharmaceutical Companies
  4. 5.2 Global ADC Drug CDMO Service Sales Value by Application
  5. 5.2.1 Global ADC Drug CDMO Service Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global ADC Drug CDMO Service Sales Value by Application (2021-2032)
  7. 5.2.3 Global ADC Drug CDMO Service Sales Value Share by Application (2021-2032)
6 ADC Drug CDMO Service Regional Value Analysis
  1. 6.1 Global ADC Drug CDMO Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global ADC Drug CDMO Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global ADC Drug CDMO Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global ADC Drug CDMO Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America ADC Drug CDMO Service Sales Value (2021-2032)
  7. 6.3.2 North America ADC Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe ADC Drug CDMO Service Sales Value (2021-2032)
  10. 6.4.2 Europe ADC Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific ADC Drug CDMO Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific ADC Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America ADC Drug CDMO Service Sales Value (2021-2032)
  16. 6.6.2 South America ADC Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa ADC Drug CDMO Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa ADC Drug CDMO Service Sales Value Share by Country, 2025 VS 2032
7 ADC Drug CDMO Service Country-level Value Analysis
  1. 7.1 Global ADC Drug CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global ADC Drug CDMO Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global ADC Drug CDMO Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global ADC Drug CDMO Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt ADC Drug CDMO Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt ADC Drug CDMO Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt ADC Drug CDMO Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza Group
  2. 8.1.1 Lonza Group Company Information
  3. 8.1.2 Lonza Group Business Overview
  4. 8.1.3 Lonza Group ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lonza Group ADC Drug CDMO Service Product Portfolio
  6. 8.1.5 Lonza Group Recent Developments
  7. 8.2 Merck KGaA
  8. 8.2.1 Merck KGaA Company Information
  9. 8.2.2 Merck KGaA Business Overview
  10. 8.2.3 Merck KGaA ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck KGaA ADC Drug CDMO Service Product Portfolio
  12. 8.2.5 Merck KGaA Recent Developments
  13. 8.3 WuXi XDC
  14. 8.3.1 WuXi XDC Company Information
  15. 8.3.2 WuXi XDC Business Overview
  16. 8.3.3 WuXi XDC ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 WuXi XDC ADC Drug CDMO Service Product Portfolio
  18. 8.3.5 WuXi XDC Recent Developments
  19. 8.4 Abbvie
  20. 8.4.1 Abbvie Company Information
  21. 8.4.2 Abbvie Business Overview
  22. 8.4.3 Abbvie ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Abbvie ADC Drug CDMO Service Product Portfolio
  24. 8.4.5 Abbvie Recent Developments
  25. 8.5 Piramal Pharma Solutions
  26. 8.5.1 Piramal Pharma Solutions Company Information
  27. 8.5.2 Piramal Pharma Solutions Business Overview
  28. 8.5.3 Piramal Pharma Solutions ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Piramal Pharma Solutions ADC Drug CDMO Service Product Portfolio
  30. 8.5.5 Piramal Pharma Solutions Recent Developments
  31. 8.6 Catalent
  32. 8.6.1 Catalent Company Information
  33. 8.6.2 Catalent Business Overview
  34. 8.6.3 Catalent ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Catalent ADC Drug CDMO Service Product Portfolio
  36. 8.6.5 Catalent Recent Developments
  37. 8.7 Sterling Pharma Solutions
  38. 8.7.1 Sterling Pharma Solutions Company Information
  39. 8.7.2 Sterling Pharma Solutions Business Overview
  40. 8.7.3 Sterling Pharma Solutions ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sterling Pharma Solutions ADC Drug CDMO Service Product Portfolio
  42. 8.7.5 Sterling Pharma Solutions Recent Developments
  43. 8.8 Axplora
  44. 8.8.1 Axplora Company Information
  45. 8.8.2 Axplora Business Overview
  46. 8.8.3 Axplora ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Axplora ADC Drug CDMO Service Product Portfolio
  48. 8.8.5 Axplora Recent Developments
  49. 8.9 Aji Bio-Pharma
  50. 8.9.1 Aji Bio-Pharma Company Information
  51. 8.9.2 Aji Bio-Pharma Business Overview
  52. 8.9.3 Aji Bio-Pharma ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Aji Bio-Pharma ADC Drug CDMO Service Product Portfolio
  54. 8.9.5 Aji Bio-Pharma Recent Developments
  55. 8.10 BSP Pharmaceuticals
  56. 8.10.1 BSP Pharmaceuticals Company Information
  57. 8.10.2 BSP Pharmaceuticals Business Overview
  58. 8.10.3 BSP Pharmaceuticals ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 BSP Pharmaceuticals ADC Drug CDMO Service Product Portfolio
  60. 8.10.5 BSP Pharmaceuticals Recent Developments
  61. 8.11 Cerbios-Pharma
  62. 8.11.1 Cerbios-Pharma Company Information
  63. 8.11.2 Cerbios-Pharma Business Overview
  64. 8.11.3 Cerbios-Pharma ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Cerbios-Pharma ADC Drug CDMO Service Product Portfolio
  66. 8.11.5 Cerbios-Pharma Recent Developments
  67. 8.12 Goodwin Biotechnology
  68. 8.12.1 Goodwin Biotechnology Company Information
  69. 8.12.2 Goodwin Biotechnology Business Overview
  70. 8.12.3 Goodwin Biotechnology ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Goodwin Biotechnology ADC Drug CDMO Service Product Portfolio
  72. 8.12.5 Goodwin Biotechnology Recent Developments
  73. 8.13 TOT Biopharm
  74. 8.13.1 TOT Biopharm Company Information
  75. 8.13.2 TOT Biopharm Business Overview
  76. 8.13.3 TOT Biopharm ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 TOT Biopharm ADC Drug CDMO Service Product Portfolio
  78. 8.13.5 TOT Biopharm Recent Developments
  79. 8.14 Huadong Medicine
  80. 8.14.1 Huadong Medicine Company Information
  81. 8.14.2 Huadong Medicine Business Overview
  82. 8.14.3 Huadong Medicine ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Huadong Medicine ADC Drug CDMO Service Product Portfolio
  84. 8.14.5 Huadong Medicine Recent Developments
  85. 8.15 Innovent Biologics
  86. 8.15.1 Innovent Biologics Company Information
  87. 8.15.2 Innovent Biologics Business Overview
  88. 8.15.3 Innovent Biologics ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Innovent Biologics ADC Drug CDMO Service Product Portfolio
  90. 8.15.5 Innovent Biologics Recent Developments
  91. 8.16 Shanghai Henlius Biotech
  92. 8.16.1 Shanghai Henlius Biotech Company Information
  93. 8.16.2 Shanghai Henlius Biotech Business Overview
  94. 8.16.3 Shanghai Henlius Biotech ADC Drug CDMO Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Shanghai Henlius Biotech ADC Drug CDMO Service Product Portfolio
  96. 8.16.5 Shanghai Henlius Biotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst